Results to your Biomarker

With over four decades of experience, ABF is a globally leading expert in bioanalysis for biomarkers of exposure related to tobacco and new emerging nicotine products, trusted by clients worldwide. We have analyzed biological samples for hundreds of (non-)clinical studies, applying the largest set of fully validated bioanalytical methods in the field of tobacco harm reduction. Our methods are regularly applied in exposure and nicotine PK studies, supporting regulatory product submissions especially in the US under FDA CTP's PMTA and MRTPA. We continuously expand our portfolio by developing and validating bioanalytical methods for new biomarkers of exposure and biomarkers of potential harm, staying at the forefront of scientific advancements. At ABF, we are committed to help our clients responsibly launch new nicotine products in the marketplace. Choose ABF for reliable and cutting-edge bioanalysis services in the field of tobacco harm reduction.

ABF is your trusted ISO17025-accredited and GLP-certified research laboratory. We specialize in providing comprehensive bioanalytical services to the pharmaceutical industry, offering unwavering support for drug development at all stages, including pharmacokinetic (PK), toxicokinetic (TK) and pharmacodynamic (PD) studies. Our expertise extends to the metabolite profiling in various matrices, the identification of unknowns, impurities, and degradation products, as well as plasma stability studies. We achieve this through the use of our state-of-the-art high-resolution mass spectrometry Orbitrap LC-MS platform. Equipped with the latest technologies for bioanalytical demands, we ensure quality, accuracy and a fast turnaround time on every project. Our highly automated data processes streamline the analytical journey, making us your preferred choice for bioanalytical services.